Clinical Trial Results, Product Approval Letter, Financial Results, and Upcoming Event - Research Reports on Receptos, Wright, United Therapeutics, Abbott and CareFusion

NEW YORK, October 31, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Receptos Inc. (NASDAQ: RCPT), Wright Medical Group Inc. (NASDAQ: WMGI), United Therapeutics Corporation (NASDAQ: UTHR), Abbott Laboratories (NYSE: ABT) and CareFusion Corporation (NYSE: CFN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7594-100free.

--
Receptos Inc. Research Reports
On October 27, 2014, Receptos Inc. (Receptos) announced that TOUCHSTONE, the Phase 2 trial of RPC1063 in ulcerative colitis (UC), met its primary endpoint and all secondary endpoints with statistical significance in patients on the 1 mg dose of RPC1063 in the 8-week induction period. The Company informed that the overall safety and tolerability profile of RPC1063 was consistent with the results of the recent Phase 2 trial in relapsing multiple sclerosis (RMS), and continues to support the potential for orally administered RPC1063 to significantly improve the treatment paradigm for UC patients. Receptos stated that this randomized, double-blind, placebo-controlled trial assessed the efficacy, safety and tolerability of two orally administered doses (0.5 mg and 1 mg) of RPC1063 in patients with UC across 57 sites in 13 countries. On the following day, Receptos' stock skyrocketed 41.36% to end the session at $95.76. The full research reports on Receptos are available to download free of charge at:

http://www.analystsreview.com/Oct-31-2014/RCPT/report.pdf

--
Wright Medical Group Inc. Research Reports
On October 27, 2014, Wright Medical Group Inc. (Wright) announced that its BioMimetic subsidiary has received an Approvable Letter from the U.S. Food and Drug Administration (FDA) for its Premarket Approval Application (PMA) for Augment® Bone Graft. According to Wright, the Approvable Letter indicates that FDA determined Augment® Bone Graft to be safe and effective as an alternative to autograft for ankle and/or hindfoot fusion indications. The Company informed that after satisfactory completion of preapproval inspections and receipt of a final approval order from the FDA, commercial sale and distribution of Augment® Bone Graft can begin in the U.S. In addition, the Company reported Q3 2014 net sales from continuing operations of $71.3 million, up 24% YoY. Further, the Company has updated its full year 2014 revenue guidance to be in the range of $298 million to $302 million, up from previous guidance of $308 million to $312 million. The Company plans to release its Q3 2014 operating results on November 5, 2014 at 3:00 p.m. CT, which will be followed by a conference call at 3:30 p.m. CT on the same day to discuss the results. The full research reports on Wright are available to download free of charge at:

http://www.analystsreview.com/Oct-31-2014/WMGI/report.pdf

--
United Therapeutics Corporation Research Reports
On October 28, 2014, United Therapeutics Corporation (United Therapeutics) reported 9.2% YoY growth in its Q3 2014 total net revenues to $329.95 million. Net product sales was $328.3 million, up 9.4% YoY due to continuous increase in the number of patients being treated with the Company's products and the launch of Orenitram (treprostinil) Extended-Release Tablets. The Company's Q3 2014 net loss stood at $25.2 million or $0.53 diluted loss per share, compared to net income of $62.7 million or $1.17 per diluted share in Q3 2013. The Company's Q3 2014 non-GAAP EPS stood at $3.91. Analysts polled by Thomson Reuters expected the Company to report EPS of $1.97 and revenues of $335.08 million for the quarter. The Company's 9M 2014 total revenue improved 13.8% YoY to $942.2 million and net income was $224.1 million, up 9.4% YoY. The full research reports on United Therapeutics are available to download free of charge at:

http://www.analystsreview.com/Oct-31-2014/UTHR/report.pdf

--
Abbott Laboratories Research Reports
On October 22, 2014, Abbott Laboratories (Abbott) released its Q3 2014 and 9M 2014 earnings. The Company reported Q3 2014 net sales of $5.1 billion, up 5.8% YoY, while operating earnings improved 54.5% YoY to $731 million. The Company's Q3 2014 net earnings stood at $538 million or $0.36 per diluted share, compared to net earnings of $966 million or $0.61 per diluted share in Q3 2013. The Company's Q3 2014 adjusted diluted EPS stood at $0.62. On average, 18 analysts polled by Thomson Reuters expected the company to report EPS (excluding special items) of $0.59 and revenue of $5.60 billion for the quarter. The Company reported 2.1% YoY growth in its 9M 2014 net sales to $15.0 billion, while net earnings declined 30.5% YoY to $1.4 billion. For Q4 2014, the Company expects GAAP EPS (including specified items) to be in the range of $0.32 - $0.34, while full-year 2014 GAAP EPS (including continuing and discontinued operations) is expected in the range of $1.22 - $1.24. The full research reports on Abbott are available to download free of charge at:

http://www.analystsreview.com/Oct-31-2014/ABT/report.pdf

--
CareFusion Corporation Research Reports
CareFusion Corporation (CareFusion) posted on the Investors section of its official website that the Company plans to hold its Annual Shareholder Meeting on November 5, 2014 at its Headquarters located at 3750 Torrey View Court, San Diego, California at 8:30 a.m. PT. The full research reports on CareFusion are available to download free of charge at:

http://www.analystsreview.com/Oct-31-2014/CFN/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review